Melanotan I vs Pramlintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan I
Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.
Full details →Pramlintide
Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.
Full details →Side-by-Side Comparison
| Aspect | Melanotan I | Pramlintide |
|---|---|---|
| Mechanism | Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure. | Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy. |
| Typical Dosage | Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing. | Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories. |
| Administration | FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results. | Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin. |
| Side Effects | Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles. | Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time. |
| Best For |